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To determine the prevalence of hepatitis E virus (HEV) 
infection among sheltered homeless persons in Marseille, 
France, we retrospectively tested 490 such persons. A to-
tal of 11.6% had immunoglobulin (Ig) G and 2.5% had IgM 
against HEV; 1 person had HEV genotype 3f. Injection drug 
use was associated with IgG against HEV.
I
nitially considered a leading cause of acute hepatitis 
in tropical and subtropical countries, hepatitis E virus 
(HEV)  is  endemic  to  industrialized  countries  (1).  Al-
though substantial data indicate that HEV infection is a 
porcine zoonosis, more information is needed about the 
epidemiology and transmission of this virus in industri-
alized countries (1–3). Homeless persons are at higher 
risk than other persons for viral hepatitis (A, B, and C) 
because their lifestyle might include injection drug use 
(IDU) and poor hygiene (4), but data on HEV prevalence 
among them are scarce (5,6). In Marseille in southeast-
ern France, ≈1,500 persons are homeless (4). Since 2000, 
shelter-based  surveys  have  been  conducted  yearly  to 
monitor infectious diseases in homeless persons (4). This 
work determined the prevalence of HEV infection in this 
population.
The Study
The surveys were reviewed and approved by the In-
stitutional  Review  Board  (CCPPCRB99/76)  (Comité  de 
Protection des Personnes Sud-Méditerranée II; www.cpp-
sudmed2.fr/)  and  the  Ethics  Committee  of  the  Medical 
School, University of the Mediterranean, Marseille). Par-
ticipating homeless persons were examined by a physician 
and interviewed by using a standardized questionnaire, and 
serum samples were collected from each participant for 
laboratory  testing.  Epidemiologic,  clinical,  and  biologic 
data that were collected varied from 1 year to another.
Serum samples collected from 490 homeless persons in 
2003, 2005, and 2006 in 2 shelters in Marseille (online Ap-
pendix Table, www.cdc.gov/EID/content/16/11/1761-appT.
htm) were tested retrospectively for immunoglobulin (Ig) 
G and IgM (EIAgen HEV kits; Adaltis Italia SpA, Rome, 
Italy) against HEV and for HEV RNA by using an in-house 
real-time reverse transcription–PCR specific for open read-
ing  frame  2  (7).  HEV  RNA  sequencing  was  performed 
when HEV RNA was detected, and genotype was assigned 
through phylogenetic analysis of open reading frame 2 par-
tial sequences (7). Serologic testing for hepatitis A, B, and 
C and for HIV were performed by using Axsym Abbott as-
says (Abbott Diagnostics Division, Wiesbaden, Germany). 
Statistical analysis was performed by using STATA version 
10.1 software (StataCorp, College Station, TX, USA). Pear-
son χ2 test, Fisher exact test, Kruskal-Wallis test, or logistic 
regression model were used when appropriate.
Mean ± SD age of homeless persons was 43 ± 14 years, 
and their mean ± SD duration of homelessness was 49 ± 84 
months. Most (96.3%) were men and were born in North Af-
rica (40.2%) or in France (33.3%) (online Appendix Table). 
Previous or ongoing IDU was reported for 4/176 (2.3%). 
Overall prevalence of anti-HEV IgG and IgM was 11.6% 
(95% confidence interval [CI] 8.9%–14.8%) (57/490) and 
2.5% (95% CI 1.3%–4.2%) (12/490), respectively. Mean 
optical density ratio (optical density/cutoff value) was 3.0 
(range 1.1–6.9) and 2.0 (range 1.1–4.6) for IgG and IgM, 
respectively. Three (0.6%; 95% CI 0.1%–1.8%) homeless 
persons were concurrently positive for HEV IgM and IgG, 
whereas 9 (1.8%; 95% CI 0.8%–3.5%) were positive only 
for IgM and 54 (11%; 95% CI 8.4%–14.1%) were positive 
only for IgG.
HEV RNA was detected in 1 homeless person, a 50-
year-old man from Romania concurrently seronegative for 
HEV IgM and IgG and for hepatitis B and C viruses. He 
reported excessive alcohol intake but no IDU. HEV geno-
type was 3f (Figure), and sequence analysis showed 98% nt 
identity with sequences previously recovered from persons 
in Spain and France. Alanine aminotransferase (ALT) level 
had been assessed in only 2/12 HEV IgM–positive home-
less persons and was elevated in 1 person (177 IU/L), in 
association with an increased γ-glutamyl transferase level 
(788 IU/L). Among the 19 homeless persons sampled in 2 
different years, 1 seroconverted; he was seronegative for 
HEV IgM and IgG in 2005 then positive in 2006 (optical 
density ratio 1.14 and 4.3, respectively). Results of HEV 
RNA testing were negative in both serum samples, and 
ALT level had not been tested.
The prevalence of HEV IgG or IgM in homeless per-
sons did not differ by year of survey; sex; place of birth; or 
serologic status for hepatitis A, B, or C viruses (online Ap-
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ness, and ALT, aspartate aminotransferase, and γ-glutamyl 
transferase levels did not differ among homeless persons 
who were positive or negative for HEV antibodies (Table). 
In the univariate analysis, previous or ongoing IDU (3/4 
vs. 19/172; p = 0.006), HIV seropositivity (2/3 vs. 16/183; 
p = 0.03), and having scabies (6/20 vs. 48/462; p = 0.02) 
were significantly associated with HEV IgG. In multivari-
ate analysis that used variables that were statistically sig-
nificant in the univariate analysis as covariates, only IDU 
was independently associated with anti-HEV IgG (adjusted 
odds ratio 26.3, 95% CI 2.5–267.1; p = 0.006).
Conclusions
We found that 11.6% (95% CI 8.9%–14.8%) of home-
less  persons  in  Marseille  were  positive  for  HEV  IgG, 
whereas  2.6%  (95%  CI  1.3%–4.2%)  had  HEV  IgM  or 
HEV RNA, indicating recent or ongoing HEV infection. 
The  HEV  IgG  prevalence  is  similar  to  that  previously 
found (6) in homeless persons in Los Angeles, California, 
USA (13.5%), and much lower than that found in 98 home-
less children in Cochabamba, Bolivia (66.3%) (5). This 
prevalence falls between seroprevalences recently assessed 
among blood donors in northern (3.2%) and southwestern 
(16.6%) France (8,9).
These comparisons should take into account the use of 
different serologic assays, in addition to differences in epi-
demiologic settings. Indeed, substantial differences have 
been observed regarding the performances of some HEV 
IgG tests (10). Moreover, the sensitivity and specificity of 
the HEV IgG assay used in our study have not been previ-
ously evaluated, which warrants a cautious interpretation of 
the results. A preliminary study conducted in 2008 of 194 
blood donors in Marseille with the same assay as that used 
in the present study found that the prevalence of HEV IgG 
was 9% (P. Gallian, unpub. data), which is similar to the 
seroprevalence we found in homeless persons. The HEV 
IgM assay we used showed good performance in patients 
with HEV genotype 3 infections in reference to PCR test-
ing (11). Thus, sensitivity, specificity, and negative predic-
tive value were 90%, 100%, and 98.8%, respectively. In 
addition, sensitivities and specificities of this test and of the 
HEV IgM ELISA 3.0 (MP Diagnostics, Singapore) did not 
differ significantly.
Although based on a small subset of homeless persons, 
our finding of the association of IDU with serologic results 
indicating past HEV infection is intriguing. This result is 
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Figure. Phylogenetic tree based on partial nucleotide sequences 
(275  bp)  corresponding  to  the  5′-end  open  reading  frame  2 
region  of  the  hepatitis  E  virus  (HEV)  genome.  Phylogenetic 
analysis included HEV sequence recovered in the present study 
(black  circle,  boldface  and  underlined;  GenBank  accession  no. 
FJ71877) and sequences corresponding to the HEV sequences 
hits with the highest BLASTn score (http://blast.ncbi.nlm.nih.gov) 
to  this  sequence  (black  triangles),  previously  recovered  in  our 
laboratory  (boldface),  and  of  previously  determined  genotypes 
and subtypes (2) (in parentheses). Shading indicates sequences 
previously  isolated  in  our  laboratory  Bootstrap  values  >60%  of 
1,000 resamplings of the data are indicated. Avian HEV sequence 
AY043166 was used as an outgroup. The names of HEV sequences 
are labeled as follows: GenBank accession no., host, and country 
of origin where recovered. Scale bar indicates number of nucleotide 
substitutions per site.
Table. Age, duration of homelessness, and liver biochemical test results for 490 homeless persons, Marseilles, France, 2003, 2005,
and 2006* 
Variable
HEV IgM HEV IgG
Positive Negative p value Positive Negative p value
Age, y, mean ± SD 37 ± 12 43 ± 14 0.13 45 ± 15 43 ± 14 0.24
Duration of homelessness, mo, mean ± SD 39 ± 38 49 ± 85 0.36 48 ± 78 49 ± 85 0.28
Liver biochemical tests,† mean ± SD, IU/L
  Alanine aminotransferase levels‡ 93 ± 119 32 ± 31 0.99 36 ± 32 32 ± 33 0.49
  Aspartate aminotransferase levels§ 49 ± 54 34 ± 43 0.99 34 ± 32 34 ± 44 0.79
J-glutamyl transferase¶ 401 ± 547 65 ± 137 0.92 76 ± 136 68 ± 147 0.44
*HEV, hepatitis E virus; Ig, immunoglobulin. 
†Assessed only in 2005 for 209 homeless persons. 
‡Data missing for 11 persons. 
§Data missing for 10 persons. 
¶Data missing for 9 persons. HEV Infection in Homeless Persons
surprising because the proportion of IDUs in our homeless 
population was low (2.3%) and much lower than propor-
tions  previously  reported  (9%–83%  (12–15).  HEV  IgG 
prevalence of 2.2%–62% has been described in IDUs, but 
a significant difference with the control group was found 
in only 2 of these studies (12–15). HEV IgG prevalence in 
Sweden was 62% (21/34) in patients who acquired acute 
hepatitis B through IDU compared with 25% (9/36) in pa-
tients with sexually acquired hepatitis B (p<0.005) (13). 
Moreover, in Italy, the prevalence was 5.4% (16/179) in 
IDUs compared with 2.6% (49/1,889) in the general popu-
lation (p<0.00001) (12). In summary, our data indicate that 
HEV  infection  occurs  in  homeless  persons,  and  further 
studies are needed to determine whether IDU is responsible 
for HEV transmission.
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